Tonix Pharmaceuticals stock halted ahead of FDA approval news
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), a micro-cap biotech company with a market capitalization of $14.7 million, filed an 8-K report with the Securities and Exchange Commission on Wednesday, announcing the submission of its audited consolidated financial statements for the quarter ended March 31, 2025. The filing is intended to meet eligibility requirements under General Instructions I.A.4 of the registration statement on Form S-3.
The report states that the company has provided its financial statements, including accompanying notes, as an exhibit to the filing. Cyclacel Pharmaceuticals is incorporated in Delaware and its common stock and preferred stock trade on the Nasdaq Capital Market under the symbols CYCC and CYCCP, respectively. According to InvestingPro data, the stock has experienced significant pressure this year, with a YTD return of -89.72%, and currently shows a Weak financial health score.
The filing was signed by Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer and Executive Director of Cyclacel Pharmaceuticals. The company’s principal executive offices are located in Kuala Lumpur, Malaysia.
This information is based on a press release statement contained in the company’s SEC filing. No additional financial results or business updates were disclosed in the document.
In other recent news, Cyclacel Pharmaceuticals, Inc. held its 2025 annual meeting of shareholders on June 30, 2025. During the meeting, shareholders re-elected five directors, including Datuk Dr. Doris Wong and Kiu Cu Seng, to serve three-year terms expiring at the 2028 annual meeting. The re-election was overwhelmingly supported, with each director receiving at least 99.97% of votes cast in favor. Additionally, no votes were cast against the directors, and abstentions varied from 15,922 to 100,082 shares. Shareholders also approved changes to the company’s equity plan, though specific details of the changes were not disclosed in the recent statement. These developments reflect continued shareholder support for the current leadership and strategic direction of Cyclacel Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.